RT Journal Article
T1 Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
A1 Franco, Fernando
A1 Carcereny, Enric
A1 Guirado, Maria
A1 Ortega, Ana L.
A1 Lopez-Castro, Rafael
A1 Rodriguez-Abreu, Delvys
A1 Garcia-Campelo, Rosario
A1 Del Barco, Edel
A1 Juan, Oscar
A1 Aparisi, Francisco
A1 Gonzalez-Larriba, Jose L.
A1 Domine, Manuel
A1 Trigo, Jose M.
A1 Cobo, Manuel
A1 Cerezo, Sara
A1 Calzas, Julia
A1 Massuti, Bartomeu
A1 Bosch-Barrera, Joaquim
A1 Garcia Coves, Paola
A1 Domenech, Marta
A1 Provencio, Mariano
K1 Epidemiology
K1 Treatment
K1 Survival
K1 Small cell lung cancer
K1 Spain
K1 Thoracic tumor
K1 Epidemiología
K1 Terapéutica
K1 Supervivencia (salud pública)
K1 Carcinoma pulmonar de células pequeñas
K1 España
K1 Neoplasias torácicas
AB Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce. Patients and methods This was an observational multicenter study that enrolled patients with lung cancer and tho racic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demo graphic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed. Results With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or  2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty per cent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overallsurvival was 9.5 months (95% CI 8.8–10.2 months), with an estimated rate of 70.3% (95% CI 67.2–73.4%), 38.9% (95% CI 35.4–42.4%), and 14.8% (95% CI 11.8–17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mor tality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1–2. Long-term survival (> 2 years) was confirmed in 6.6% of patients,showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis. Conclusion This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.
PB Public Library of Science
YR 2021
FD 2021-06-02
LK http://hdl.handle.net/10668/4053
UL http://hdl.handle.net/10668/4053
LA en
NO Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. PLoS One. 2021 Jun 2;16(6):e0251761
DS RISalud
RD Apr 18, 2025